News about Suzhou, China
Stay current with all the latest and breaking news about Suzhou, China, compare headlines and perspectives between news sources on stories happening today. In total, 60 stories have been published about Suzhou, China which Ground News has aggregated in the past 3 months.
Weather
47°F
Thursday
42° | 62°F
Friday
50° | 73°F
Saturday
54° | 73°F
Sunday
40° | 50°F
Monday
36° | 51°F
Tuesday
46° | 59°F
Local News Publishers
Suggest a source
Looking for a source we don't already have? Suggest one here.Top Suzhou, China News

Suzhou, China · SuzhouSAN FRANCISCO and SUZHOU, China, Dec. 6, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other…See the Story
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
80% Center coverage: 25 sources

Suzhou, China · SuzhouSUZHOU, China, Dec. 3, 2025 /PRNewswire/ -- On December 3, 2025 (local time in Arizona, USA), ImmVira Group ("ImmVira" or the "Company") announced a poster presentation at the 26th Annual Meeting of the Society of Urologic Oncology (SUO 2025). The…See the Story
High Response in Bladder Cancer: Immvira Announced Its MVR-T3011 Latest Clinical Results in BCG-Unresponsive Bladder Cancer Patients at 2025 Annual Meeting of the Society of Urologic Oncology
59% Center coverage: 22 sources

Suzhou, China · SuzhouSAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major…See the Story
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
88% Center coverage: 18 sources